Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 298,780 shares, a growth of 528.9% from the May 14th total of 47,507 shares. Based on an average trading volume of 667,164 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, Daiichi Sankyo presently has a consensus rating of “Hold”.

Daiichi Sankyo Price Performance

OTCMKTS DSNKY traded up $0.49 on Thursday, reaching $15.86. 393,779 shares of the stock traded hands, compared to its average volume of 430,448. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50. The company has a market cap of $30.04 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.10 and a beta of -0.16. The firm’s fifty day simple moving average is $16.98 and its 200 day simple moving average is $19.20. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, research analysts predict that Daiichi Sankyo will post 0.94 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.